ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

8302	Companies
115129	Keywords
55450	Articles
62533	Press releases

Home
Companies
ABIVAX

BRIEF

published on 04/30/2024 at 18:05, 6 months 21 days ago

ABIVAX reports the number of shares and voting rights as of March 31, 2024

Share Capital Voting Rights Financial Markets Authority Abivax Regulatory Information
BRIEF

published on 04/05/2024 at 22:05, 7 months 16 days ago

Abivax Announces Submission of Financial Reports to French and U.S. Regulatory Agencies

Abivax Financial Reports Chronic Inflammatory Diseases Regulatory Agencies Webcast Announcement
PRESS RELEASE

published on 04/05/2024 at 22:00, 7 months 16 days ago

Abivax publishes financial reports with the French and U.S. securities regulatory agencies
Abivax publishes 2023 financial reports with French and U.S. securities regulators, including annual report and governance information

Abivax Financial Reports Regulatory Agencies French Securities U.S. Securities
BRIEF

published on 04/02/2024 at 08:35, 7 months 19 days ago

Abivax Reports 2023 Financial Results and Operational Update

Financial Results Abivax Obefazimod Ulcerative Colitis Nasdaq IPO
PRESS RELEASE

published on 04/02/2024 at 08:30, 7 months 19 days ago

Abivax reports 2023 financial results and operational update
Abivax reports 2023 financial results & operational update. Raised EUR 500M, aims to finance operations till Q4 2025. Webcast on April 8, 2024

Financial Results Fundraising Abivax Webcast Operational Update
BRIEF

published on 03/27/2024 at 18:05, 7 months 25 days ago

ABIVAX publishes its number of shares and voting rights as of February 29, 2024

Euronext Paris Share Capital Voting Rights Abivax Regulation
BRIEF

published on 02/23/2024 at 18:00, 8 months 27 days ago

ABIVAX announces an update on its share capital and voting rights

Share Capital Voting Rights Biotechnology Abivax Financial Transparency
PRESS RELEASE

published on 02/13/2024 at 08:30, 9 months 8 days ago

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
Abivax to present four abstracts on obefazimod for ulcerative colitis at 19th ECCO Congress, including a sponsored symposium on emerging treatment mechanisms. Event details available on ECCO website

Abivax Obefazimod Ulcerative Colitis ECCO Congress Scientific Symposium
PRESS RELEASE

published on 02/07/2024 at 08:30, 9 months 14 days ago

Abivax appoints Ana Sharma as Vice President, Global Head of Quality
Abivax appoints Ana Sharma as Vice President, Global Head of Quality. Ana Sharma brings over 20 years of experience in the biopharmaceutical industry and has a strong track record in quality and GxP compliance

Abivax Ana Sharma Biopharmaceutical Industry Quality Compliance GxP
PRESS RELEASE

published on 02/02/2024 at 08:30, 9 months 19 days ago

Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
Abivax updates obefazimod Phase 2b clinical program in Crohn’s disease following FDA feedback. Trial design modification to align with FDA recommendations. Patient enrollment to start in Q3 2024

Abivax Obefazimod Crohn’s Disease Phase 2b Clinical Trial FDA Feedback

Accesswire

Published on 11/22/2024 at 00:00, 4 hours 58 minutes ago

Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 6 hours 53 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 7 hours 8 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 8 hours 43 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 8 hours 48 minutes ago

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 19:01, 9 hours 57 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 10 hours 22 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 10 hours 59 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 11 hours 6 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 11 hours 7 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.

Les Echos

Published on 11/21/2024 at 06:58, 22 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 9 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 11 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 11 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 21 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE